Cancer-targeted IL-2 nanoparticle therapy
Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy
['FUNDING_R01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-11263718
A new treatment that uses nanoparticles to deliver a modified IL-2 immune protein that activates inside acidic tumors to boost tumor-killing T cells while reducing side effects for people with solid tumors.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11263718 on ClinicalTrials.gov |
What this research studies
This project develops nanoparticles that carry a modified form of the immune protein IL-2 that remains inactive in the bloodstream and activates in the acidic tumor environment. The modified IL-2 (a "superkine") is engineered to favor CD8 T cells and natural killer cells while avoiding immune-suppressive regulatory T cells. Nanoparticle delivery and protein fusion strategies are used to extend circulation time and limit systemic exposure to reduce toxicities. The team will combine protein engineering and nanoparticle design and will test the approach in laboratory and animal models as a step toward future clinical trials.
Who could benefit from this research
Good fit: Adults with solid tumors—particularly melanoma or renal cell carcinoma—or other cancers open to experimental immunotherapy and willing to enroll in early-phase clinical trials would be the most likely candidates.
Not a fit: Patients with severe autoimmune disease, those unable to tolerate immunotherapy, or patients whose tumors do not engage immune responses may not benefit from this approach.
Why it matters
Potential benefit: If successful, this could provide a safer, more effective IL-2 immunotherapy that better activates tumor-killing immune cells with fewer toxic side effects.
How similar studies have performed: High-dose IL-2 has cured some kidney and skin cancers and engineered long-acting IL-2 variants have shown promise, but pH-activated IL-2 delivered by nanoparticles is a newer strategy that is mostly at the preclinical stage.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAO, JINMING — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: GAO, JINMING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.